Somatic mutations in TP53 are very common in human cancer (Hollstein et al., 1991) . This 393 amino acid nuclear phosphoprotein, mapping to 17pl3.1, is active as a transcription factor and binds DNA in a sequence-specific manner. Baker et al. (1989) showed that mutations in the TP53 gene of two colorectal cancers affected a highly conserved region of the gene, and was associated with allelic losses of the wild-type TP53 gene. This suggested that TP53 acts as a tumour-suppressor gene (TSG). These findings were later generalised to a number of human cancers , but it was emphasised in this paper that mutation of TP53 was not always associated with LOH on 17p.
Previous studies of TP53 in sporadic OC have shown that mutations are present in up to 80% of OCs (Marks et al., 1991; Mazars et al., 1991; Okamoto et al., 1991; Kohler et al., 1993a,b; Kupryjanczyk et al., 1993; Milner et al., 1993; Teneriello et al., 1993) . Taken together, these studies demonstrate that (1) Mutation of TP53 is usually accompanied by overexpression of TP53 protein as detected by most of the anti-p53 monoclonal antibodies and vice versa, but there are a number of tumours where this relationship does not hold. (2) Mutation of TP53 is commonly associated with LOH of the wild-type allele, but often there is LOH over the whole of chromosome 17. (3) TP53 mutation occurs before metastatic spread, and is less common in early-stage than late-stage disease. (4) There is no strong evidence that any particular type of mutation (transition, tranverserion, mutation hotspot) is overrepresented in OC.
(5) Mutations in TP53 and RASK are not seen in the same tumour.
(6) There is no clear prognostic information to be gathered from the presence of a TP53 mutation in any given OC.
An amplified murine gene, mdm2 (murine double minute 2) was cloned from a transformed mouse 3T3 cell line (CahillySynder et al., 1987 (Foulkes et al., 1993a) . Table I shows the histopathological subtype of each tumour studied. Cryostat sections were taken from each tumour to ensure that stromal 'contamination' was kept to a minimum. DNA was then extracted from the tumours and lymphocytes as described previously.
TP53 LOH studies
There were carried out as described in Foulkes et al. (1993b) . LOH was studied using a bglII restriction fragment length polymorphism (RFLP) within the TP53 gene (De La Calle et al., 1990 ) and using the highly informative dinucleotide repeat that lies near TP53 (Jones and Nakamura, 1992 intensity of the autoradiographic signals obtained were compared with DNA loading by comparison with previous hybridisation signals performed on the same blots. Additionally, all blots were hybridised with a probe for the RET protooncogene (Mulligan et al., 1993) , which is a single-copy gene on chromosome 10q1 1.2.
Results
Mutation, immunohistochemistry and loss of heterozygosity for TP53 We analysed our series of tumours for aberrations in TP53 by SSCP followed by direct sequencing, IHC with three anti-p53 antibodies and by LOH using a highly polymorphic dinucleotide repeat marker. Using this combined approach we have shown that 19/36 OCs had mutations in TP53 by DNA sequence analysis, performed as a result of an aberrantly migrating PCR fragment seen on SSCP (Table I) . Eighteen of these mutations were missense mutations and one was a deletion (tumour 47 showed a very clear band shift with SSCP analysis, but despite many attempts, this tumour could not be sequenced and therefore this tumour has been included as 'mutation, but not identified'). The 18 base substitutions seen in this series of 35 OCs were all transitions, with 50% being at GC->AT, (39% at CpG sites and 11% at other sites) and 50% were AT->GC transitions. Five out of these 9 AT-* GC transitions were at codon 220, TAT-* TGT, changing the amino acid sequence from tyrosine to cysteine. Thus no transversions or complex substitutions were seen. The deletion (tumour 85) would result in a frame-shift and therefore would be likely to produce a truncated protein. This case was positive for p53 IHC.
Twenty-three of 43 OCs (53%) were positive by IHC with the anti-p53 antibodies PAb 421, D07 or CM1. All three antibodies were used where tissue was available, and no discordant results in terms of positive vs negative immunostaining were obtained using these three antibodies. The correlation between mutation in TP53 and positive IHC was highly significant (Fisher's exact test, P<0.001) (Table II) . However, the common mutation in our series is codon 220, TAT>TGT, Tyr>Cys and the IHC results were not completely concordant for these five tumours. The five tumours were no. 10, a serous papillary adenocarcinoma, (SPAC); no.
24, an undifferentiated adenocarcinoma, (AC/UD); no. 42, an endometrioid carcinoma; no. 64, an AC/UD; and no. 83, a SPAC. Tumour 10 showed clear LOH at TP53 and a mutation in exon 6, as did the other four cases (Table I) .
Despite the differing histology, all except tumour 10 were positive for IHC with the anti-p53 antibodies used. It is possible that another mutation has occurred in this tumour outside exons 5-8 which prevents protein from being produced, resulting in negative IHC. Alternatively, the protein may have become destabilised in the period between tumour removal and snap freezing, although from our positive results with this tumour using other antibodies (not shown) this seems unlikely. There were two other tumours that had TP53 
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chromosome 17 are 'driving' the LOH. Similarly, there are three cases with mutations but no LOH. As these are all late stage, moderate-to-high-grade tumours, it seems unlikely that in these cases TP53 mutation is an early event (with LOH to follow). Examples of LOH at TP53, mutation in TP53 and positive IHC with monoclonal antibody D07 are shown in Figure 1 (tumour 80). Interestingly, this tumour shows complete LOH but the wild-type genotype is clearly visible on the sequencing gel, suggesting that LOH with reduplication or recombination preceded mutation in TP53.
MDM2 amplifications and over-expression Southern blots of tumour and normal DNA were probed with an MDM2 cDNA, pHDM. The intensity of the hybridising bands was compared with the DNA loaded onto the gel by assessment of both ethidium bromide staining and the hybridisation signals obtained with a probe for the RET proto-oncogene, an example of which is shown in Figure 2 . This probe detects a single copy gene on chromosome 1Oql 1.2, a region that is not noted for its deletion or amplification in ovarian cancers. Additionally these filters have been hybridised with a variety of polymorphic DNA probes in previous LOH studies and these assisted in verifying the DNA loading. MDM2 amplification, if present, is generally in the order of 5-8 fold which is easily detectable on Southern blots (Reifenberger et al., 1993) . However, we found no discernable variation in MDM2 hybridisation signals among the 32 tumours studied. Interestingly, no DNA a amplification was evident in tumour 73 which was positive for MDM2 by IHC (see below). Thirty-seven tumours were examined for MDM2 protein overexpression by IHC using the antibody IF-2. Only one tumour, 73, showed positive MDM2 IHC (Figure 3 ). This tumour was negative for p53 IHC and TP53 mutation. Interestingly, this was a mixed mullerian tumour with histological features similar to sarcomas, a tumour type where MDM2 amplification and over-expression is frequently observed.
Discussion
Here we present the first account of a combined approach to the analysis of TP53 and MDM2 aberrations in sporadic OC. We have demonstrated that The spectrum of mutations we observed differ slightly from the experience of other groups, in that all the missense mutations we found were transitions, whereas in a review of all OC cases reported 93/128 mutations were transitions (73%) and 35/128 (27%) were transversions (Kohler et al., 1993b) . The smaller numbers in our series may account for the differences seen. This study supports the conjecture that environmental toxins are unlikely to be responsible for TP53 mutations in OC (Kohler et al., 1993b) .
It has been suggested that mutations in TP53 and amplification of MDM2 in the same tumour are biologically redundant, in that both alterations have the same effect: loss of p53 function. Thus, in our series of OCs we studied MDM2 amplification and over-expression in order to determine whether MDM2 was aberrant in OC and if so, whether amplification and/or overexpression was limited to those tumours without TP53 alterations. Of 43 OCs available, 32 were studied by Southern blotting using an MDM2 cDNA and 37 by IHC using the antibody IF-2. No tumours showed amplification, and only one tumour, a mixed miillerian tumour, demonstrated overexpression. Therefore in OC, regulation of TP53 does not appear to be mediated by MDM2 overexpression.
The tumour showing positive IHC with IF-2, tumour 73, is negative for IHC with anti-p53 antibodies and does not have a mutation in exons 5-8 of TP53. This mixed miillerian tumour is, to our knowledge, the only ovarian tumour to be described that demonstrates an overexpression of MDM2 protein. The fact that the tumour displays sarcomatous features is intriguing, as it is soft-tissue sarcoma (Leach et al., 1993; Cordon-Cardo et al., 1994; Florenes et al., 1994a; Patterson et al., 1994) , and to a lesser extent gliomas (Reifenberger et al., 1993) and osteosarcomas (Ladanyi et al., 1993; Florenes et al., 1994a) , that most commonly show amplification and/or overexpression of MDM2. There may be particular features of the differentiation of mesenchymal tissue that favour the accumulation of quantitatively abnormal MDM2 protein.
The presence of overexpressed MDM2 in the absence of amplification has been reported in two series of sarcomas (Cordon-Cardo et al., 1994; Florenes et al., 1994a) and, perhaps surprisingly, in 25 out of 87 bladder cancers in one series (Lianes et al., 1994) . In this latter series, only one tumour had DNA amplification and overexpression, which suggests that MDM2 overexpression in bladder cancer may have different biological implications from that seen in sarcomas, especially as the same group found that overexpression was significantly associated with low-grade, early-stage tumours. The significance of overexpression of MDM2 without amplification is uncertain: it has been suggested that in this context MDM2 expression (to levels detectable by IHC) may be a response to wild-type TP53 (Meltzer, 1994) . Our findings with tumour 73 would support this view. However, we did not see any MDM2 overexpression in the other 16 OCs in our series that lacked mutations in TP53 exons 5-8.
The spectrum of tumours that show MDM2 amplification and/or overexpression has been studied by several groups. In general, it appears that MDM2 amplification and/or overexpression is present in up to one-third of all soft-tissue sarcomas and about 10% of glioma and metastatic osteosarcomas. In contrast, MDM2 amplification and/or overexpression is very uncommon or absent in colon carcinoma (Oliner et al., 1992 ), Ewing's sarcoma (Kovar et al., 1993) , gastric carcinoma (Oliner et al., 1992) , hepatoblastoma (Waber et al., 1993) , leukaemia (Ridge et al., 1994) , malignant melanoma (Florenes et al., 1994b) , myelodysplastic syndromes (Preudhomme et al., 1993) , neuroblastoma (Waber et al., 1993) , oesophageal carcinoma (Esteve et al., 1993) , ovarian carcinoma (this report), upper aerodigestive tract squamous carcinoma (Waber et al., 1993) , uterine cervix carcinoma (Kessis et al., 1993) or Wilms' tumour (Waber et al., 1993) . The question of MDM2 involvement in bladder cancer is unresolved as, though amplification of MDM2 was rare in two independent studies (2/50, Habuchi et al., 1994; 1/87, Lianes et al., 1994) , the latter group found that overexpression without amplification was common (25/87).
Our results confirm the importance of TP53 in OC. Indeed, aberrant TP53 expression is one of the commonest genetic defects seen in human cancers (Hollstein et al., 1991) . The abnormal expression commonly results from mutations in the coding region of TP53. However, the finding that MDM2, a protein that binds p53, was amplified in sarcomas that did not show mutations in TP53 (Oliner et al., 1992) suggested that this might be an alternative way of abrogating p53 function. The importance of MDM2 in soft-tissue sarcomas is clear, but taking all-the published data together it appears that in many human cancers p53 is not commonly inactivated by sequestration through MDM2 amplification. It may be that MDM2 has a particular role in mesenchymal tumours, but MDM2 amplification in the common adult cancers (where TP53 mutations are frequent) is uncommon.
